Noopept
UnregulatedAlso known as: GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, Omberacetam
Nootropic & NeuroprotectiveLast reviewed: April 28, 2026
A synthetic dipeptide-derived nootropic developed in Russia, structurally related to the racetam family but approximately 1000x more potent by weight. Approved as a prescription drug in Russia for cognitive impairment.
Mechanism of Action
Modulates AMPA and NMDA glutamate receptors, enhancing long-term potentiation (LTP) — the cellular basis of learning and memory. Increases BDNF and NGF expression in the hippocampus. Also has anxiolytic properties via modulation of inhibitory neurotransmission.
Common Uses
- Cognitive enhancement
- Memory improvement
- Neuroprotection
- Anxiety reduction
- Post-concussion recovery
Known Risks
- Headache (most common)
- Irritability at high doses
- Insomnia if taken late in day
- Limited Western clinical data
- Long-term safety unknown
Regulatory Status
No FDA regulatory category. Available as a research chemical in the US. Approved as a prescription drug in Russia. Not a dietary supplement under US law.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Oral (sublingual or capsule)
Typical Dose
10–30 mg
Frequency
1–3x daily
Cycle Length
1–3 months on, 1 month off
Sublingual absorption is faster and more bioavailable. Start at 10 mg to assess tolerance. Often stacked with a choline source (Alpha-GPC or CDP-Choline).
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.